Banzhu Shegan Powder Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions is released as a dry botanical active pharmaceutical ingredient with route-specific controls for particle size, moisture, microbial burden, and endotoxin content. The assigned model code identifies the multi-dosage-form grade; route-specific suffixes on the certificate of analysis distinguish the tablet/capsule fraction from the injection/solution fraction. The material is not an unprocessed herb powder. Release documentation for solid oral grades typically reports loss on drying ≤8.0%, total ash ≤15.0%, acid-insoluble ash ≤5.0%, and total aerobic microbial count ≤10⁴ CFU/g by Ph. Eur. 2.6.12. For injectable and solution intermediates, the specification is tightened to bacterial endotoxins <0.5 EU/mg by Ph. Eur. 2.6.14 and bioburden <10² CFU/g by ISO 11737-1:2018. Sieve analysis is performed by Ph. Eur. 2.9.38; bulk and tapped density are reported by Ph. Eur. 2.9.34. Heavy metals are controlled at ≤20 ppm by Ph. Eur. 2.4.8 for oral grades and ≤10 ppm for injection grades. Residual solvents, when ethanol-based extraction is used, are controlled under Ph. Eur. 2.4.24 with residual ethanol <5000 ppm. The injection-grade fraction is double-bagged in LDPE liners inside an HDPE drum with desiccant and nitrogen purge when ambient RH during storage exceeds 60%. This multi-grade release system supports batch release under EU Directive 2001/82/EC for veterinary medicinal products and 21 CFR 211 when the finished dosage form is manufactured in the United States.

Why Does a Botanical API Require Route-Specific Particle-Size Reduction Instead of a Single Milled Fraction?

Particle-size distribution controls die filling, capsule dosator packing, suspension syringeability, and premix homogeneity. In rotary tablet compression, a D90 above 250 µm with fibrous botanical morphology can produce weight variability above 3.0% RSD on a 10-station B-tooling press at 20–40 rpm. Wet granulation with povidone K30 at 3.0 wt% or pregelatinized starch at 5.0 wt% is generally required; the API D90 should be below 180 µm before granulation to avoid undissolved fiber agglomerates that reduce tablet hardness. Capsule filling on dosator machines requires powder bed compressibility. A Carr Index above 30% produces unstable die cavity packing; addition of colloidal silicon dioxide at 0.5–1.5 wt% and microcrystalline cellulose at 10–20 wt% is often necessary to bring fill-weight RSD below 2.0%. For injection intermediates, high-pressure homogenization at 500–1000 bar is used after reconstitution or during compounding; this is feasible only when the dry API D90 does not exceed 75 µm and a 150 µm security sieve removes cellulosic debris. A single milled fraction cannot satisfy all routes simultaneously because the optimum flow characteristics for tablet compression are opposite to the dispersion requirements for injectable suspensions.

Fluid-bed granulation of a 65 wt% API, 25 wt% lactose monohydrate, 10 wt% povidone K30 formulation at inlet air temperature 60°C, spray rate 15 g/min, and air volume 120 m³/h produces granules with mean size 150–250 µm. Endpoint moisture of 2.0–4.0% is confirmed by loss on drying. If API moisture exceeds 8.0% before charging, the spray rate is reduced to 10 g/min to avoid defluidization. In a high-shear granulator, torque-rheometry wet massing shows a target main impeller torque of 8–12 N·m for 120–180 s; over-granulation above 240 s increases fines below 75 µm and lowers tablet hardness by up to 20%. These are processing boundaries observed in production-scale trials; they are not intended as universal formulation instructions.

Release Specification Boundaries for Dry Blending, Wet Granulation, and Liquid Incorporation

Table 1 summarizes the release controls applied to the same botanical source when designated for different manufacturing routes. The limits are method-specific and should not be treated as interchangeable across routes.

In a 100 kg V-blender operated at 12 rpm for 15 min, a 1.0 wt% active marker in a direct compression blend should reach an RSD below 5.0% when sampling at 10 positions. If the API is not pre-sieved through a 500 µm screen, agglomerates persist and content uniformity fails USP <905> acceptance value 15.0. For medicated feed premixes, two-stage dilution is required: first a 1:10 intermediate premix with ground corn or rice hulls, then final feed incorporation. Skipping the intermediate step increases carryover and can raise assay RSD above 10% in the final feed. For dry powders and granules, electrostatic adhesion to polycarbonate and acrylic contact surfaces is documented; dedicated scoops and vacuum transfer with HEPA filtration are required in injection-grade areas.

When the Same Powder Grade Must Not Be Used Across All Routes

Route substitution creates measurable failures. A tablet-grade fraction with D90 ≤250 µm and loss on drying ≤8.0% is not suitable for injection compounding because the coarse fiber fraction can obstruct a 0.22 µm clarifying filter, increase extrusion force in high-pressure homogenizers, and raise particulate matter counts above Ph. Eur. 2.9.19 limits. Conversely, an injection-grade micronized fraction with D90 ≤75 µm and loss on drying ≤5.0% is poorly flowable and will not feed consistently into a tablet die without large glidant concentrations. The resulting Carr Index is high, and tablet weight variability exceeds the acceptance range. The product therefore is not a universal single-mesh powder. Batch records must specify the route-specific grade code and the mill screen size used to generate it.

For injectable suspensions, the API is dispersed in water for injection containing 0.5% sodium carboxymethylcellulose and 0.1% polysorbate 80. The dispersion is passed through a high-shear mixer at 8000–12000 rpm for 5 min, then a high-pressure homogenizer at 800 bar for 3 cycles. Final particle size D90 is checked by laser diffraction; if D90 remains above 20 µm, syringeability through a 21G needle may exceed 25 N extrusion force and fail Ph. Eur. 2.9.19 particulate matter limits. Because the botanical matrix contains cellulosic debris, a 150 µm pre-filtration screen is mandatory before terminal filtration. Terminal 0.22 µm filtration is not feasible for this insoluble dispersion; therefore, aseptic processing or terminal sterilization of the final container is selected based on product-specific stability data. Published data for this specific configuration are limited; process qualification must be repeated in the target facility.

Assay Interpretation and the Limits of Interchangeability with Synthetic Mucolytics

Unlike a single-molecule synthetic active pharmaceutical ingredient such as bromhexine hydrochloride or ambroxol hydrochloride, this product is a multi-component botanical matrix. Its assay is expressed as total marker components normalized to a reference batch, not as a single chemical entity. Dose cannot be extrapolated from the molar mass of a pure compound; finished dosage units are validated by uniformity of dosage units testing under Ph. Eur. 2.9.40 or USP <905>. The product is not interchangeable with purified synthetic mucolytics on an equal-weight basis. Table 2 summarizes the distinction.

Cleaning validation in multi-product facilities uses swab acceptance limits for total organic carbon and marker content. Where the API is processed before a synthetic product, a worst-case carryover limit of 10 mg/kg in the next product is typically derived from 0.001 of the lowest therapeutic dose. Addition of strong alkalis or amines to aqueous solutions of the API can increase pH above 9 and degrade glycosidic marker compounds; buffering to pH 4.5–6.5 with citrate or phosphate is recommended. Dry-cleaning with compressed air is not permitted in injection-grade areas; vacuum systems with HEPA filtration are used. The API should not be stored in direct contact with strong oxidizing agents because residual peroxide from sanitization can oxidize phenolic marker compounds and shift assay recovery. Operational stability is maintained when unopened drums are stored at ≤25°C and ≤60% RH; after opening, the material is re-sealed with desiccant and used within 30 days for injection-grade fractions or 90 days for solid oral fractions.